Liraglutide 3.0 mg was also beneficial in reducing BW in adolescents with obesity compared to placebo (3.2% vs
Gastrointestinal adverse effects, such as nausea, vomiting, constipation, and diarrhea, are common with injectable obesity management medications and a frequent reason for discontinuation
doi:10.1111/eci.13377 28
J3490 has no single drug name because it covers any unclassified injectable
Track your own metrics weekly: weight, waist circumference, how your clothes fit, energy levels, sleep quality, and any biomarkers your provider monitors
Murtaza Khorakiwala, MD, set the context with understated confidence: We started off as an Indian company 55 years back in a generic business and over the last 25 years, we have evolved into a global company where 70% of our revenue is outside India